Pediatrix Medical Group, Inc. Revenue 2008–2025
Pediatrix Medical Group, Inc. reported $1.91B of revenue for fiscal 2025. That was 4.9% lower than fiscal 2024. Compared with fiscal 2020, the change was +10.4%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $1.91B | -4.9% |
| FY 2024 | $2.01B | +0.9% |
| FY 2023 | $1.99B | +1.1% |
| FY 2022 | $1.97B | +3.2% |
| FY 2021 | $1.91B | +10.2% |
| FY 2020 | $1.73B | -2.6% |
| FY 2019 | $1.78B | +3.3% |
| FY 2018 | $1.72B | -47.0% |
| FY 2017 | $3.25B | +2.2% |
| FY 2016 | $3.18B | — |
| FY 2015 | $0 | — |
| FY 2014 | $0 | — |
| FY 2013 | $0 | — |
| FY 2012 | $0 | — |
| FY 2011 | $0 | — |
| FY 2010 | $0 | — |
| FY 2009 | $0 | — |
| FY 2008 | $0 | — |
Source: Pediatrix Medical Group, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open MD 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Pediatrix Medical Group, Inc. reported $1.91B of revenue for fiscal 2025. That was 4.9% lower than fiscal 2024. Compared with fiscal 2020, the change was +10.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Pediatrix Medical Group, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freePediatrix Medical Group, Inc. — frequently asked questions
What is Pediatrix Medical Group, Inc.'s revenue?
Pediatrix Medical Group, Inc. (MD) reported revenue of $1.91B for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Pediatrix Medical Group, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.